×
About 1,433,082 results

Determinants of COVID-19 disease severity in patients with cancer
https://www.nature.com/articles/s41591-020-0979-0

Infigratinib Demonstrates Clinical Activity Across Settings in Urothelial Cancer
https://www.onclive.com/view/infigratinib-demonstrates-clinical-activity-across-settings-in-urothelial-cancer

May 31st, 2020

TRK Inhibitor Continues to Show Multi-Cancer Effects
https://www.medpagetoday.com/meetingcoverage/asco/86834

Jun 1st, 2020

Hydroxychloroquine, Azithromycin Combo Risky for Cancer Patients
https://www.medpagetoday.com/meetingcoverage/ascovideopearls/87062

Jun 14th, 2020

Second Surgery Gets OS Win in Recurrent Ovarian Cancer
https://www.medpagetoday.com/meetingcoverage/asco/86836

Jun 1st, 2020

Dr. Gwin on the Mechanism of Action of Alpha-TEA in HER2-Positive Metastatic Breast Cancer
https://www.onclive.com/view/dr-gwin-on-the-mechanism-of-action-of-alphatea-in-her2positive-metastatic-breast-cancer

Jun 4th, 2020

Surgery for Metastatic Breast Cancer Fails to Boost Overall Survival
https://www.medpagetoday.com/meetingcoverage/asco/86802

May 31st, 2020

Pembrolizumab May Help in Triple-Negative Breast Cancer
https://www.medpagetoday.com/meetingcoverage/asco/86804

May 31st, 2020

Dr. Zakashansky on the Benefit of Maintenance Olaparib in BRCA+ Ovarian Cancer
https://www.onclive.com/view/dr-zakashansky-on-the-benefit-of-maintenance-olaparib-in-brca-ovarian-cancer

Jun 1st, 2020

Dr. Poveda on the Results of the SOLO2 Trial in Ovarian Cancer
https://www.onclive.com/view/dr-poveda-on-the-results-of-the-solo2-trial-in-ovarian-cancer

May 31st, 2020

Expert Perspective on ASCO20 Lung Cancer Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200235/full/

New Kidney Cancer Research From the ASCO20 Virtual Scientific Program Demonstrates an Exciting, Evolving Field
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200216/full/

Jun 24th, 2020 - There used to be a paucity of options for managing advanced renal cell cancer (RCC) with a high toxicity profile including traditional chemotherapy, interferon, and interleukins. With the advent of tyrosine kinase inhibitors (TKIs) in 2007 followed by immunotherapy over the past few years, a paradigm shift emerged in managing this increasingly prevalent disease with its associated high m...

ECOG-ACRIN Trial Reassures Clinicians, Patients That Locoregional Therapy Is Not Beneficial for Stage IV Metastatic Breast Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200218/full/

Jun 23rd, 2020 - For patients with stage IV metastatic breast cancer and an intact primary tumor (ITP), the early initiation of locoregional treatment (LRT) was not associated with longer survival or improvements in health-related quality of life (HRQoL) compared with systemic therapy alone, according to a phase III clinical trial (Abstract LBA2). These findings appear to add to a robust evidence base th...

Breast Cancer Research at ASCO20 Virtual Scientific Program Highlights New Avenues and Better Outcomes
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200222/full/

Jun 24th, 2020 - The ASCO20 Virtual Scientific Program featured a variety of important and innovative breast cancer research. The following are some of the studies with potential to significantly impact clinical practice and patient outcomes, as selected by ASCO Daily News Expert Panel member Arielle Heeke, MD, of the Levine Cancer Institute.

Top Lung Cancer Research Presented at the ASCO20 Virtual Scientific Program Has Implications for Clinical Practice
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200223/full/

Jun 24th, 2020 - Although the ASCO Annual Meeting felt much different this year given the virtual format, the quality of research presented at the meeting was undiminished, particularly in the field of lung cancer. ASCO Daily News Expert Panel member Jared Weiss, MD, of the University of North Carolina School of Medicine, reviewed the most influential lung cancer research presented during the ASCO...

Researchers gain insight into factors influencing immunotherapy response in kidney cancer
https://www.healio.com/news/hematology-oncology/20200710/researchers-gain-insight-into-factors-influencing-immunotherapy-response-in-kidney-cancer

Jul 9th, 2020 - Tumor mutational burden is considered a hallmark indicator of a tumor’s potential for response to immunotherapy. PD-1 checkpoint inhibitors such as pembrolizumab (Keytruda, Merck) and nivolumab (Opdivo, Bristol-Myers Squibb) have been shown to be more effective in treating tumors with high mutational burden. However, despite having only a moderate number of mutations, advanced clear cell ren...

Olaparib shows 1-year survival benefit in recurrent ovarian cancer, BRCA mutations
https://www.healio.com/news/hematology-oncology/20200707/olaparib-shows-1year-survival-benefit-in-recurrent-ovarian-cancer-brca-mutations

Jul 6th, 2020 - Overall survival results from SOLO-2 showed patients with recurrent ovarian cancer and germline BRCA mutations added a year of life when treated with olaparib only, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Patient survival greatly impacted by selection for ovarian cancer relapse surgery
https://www.healio.com/news/hematology-oncology/20200707/patient-survival-greatly-impacted-by-selection-for-ovarian-cancer-relapse-surgery

Jul 6th, 2020 - Studies presented during the ASCO2020 Virtual Scientific Program showed the benefit of validated selection tools in pursuing surgical measures for ovarian cancer relapse, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

ASCO 2020 Heralds a Handful of Influential Data Across Breast Cancer Settings
https://www.onclive.com/view/asco-2020-heralds-a-handful-of-influential-data-across-breast-cancer-settings

Jul 9th, 2020

Coronavirus Disease 2019 (COVID-19) Resources for the Cancer Care Community
https://www.nccn.org/covid-19/
NCCN

NCCN recognizes the rapidly changing medical information relating to COVID-19 in the oncology ecosystem, but understands that a forum for sharing best practices and specific institutional responses may be helpful to others. Therefore, we are expeditiously providing documents and recommendations developed by NCCN Member Institutions or Guideline Panels as resources for oncology care providers. ...